Glucosamine Sulfate Bioavailability

Comparative Bioavailability of Crystalline and Regular Glucosamine Sulfate: A Randomized Crossover Study in Healthy Adults

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06971484

Enrollment

Registered

2025-05-14

Start date

2025-01-06

Completion date

2025-04-30

Last updated

2025-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bioavailability and Pharmacokinetics

Keywords

glucosamine, crystalline, pharmacokinetics, bioavailability

Brief summary

This study aims to compare the pharmacokinetics and bioavailability of crystalline glucosamine sulfate and regular glucosamine sulfate using a double-blind, randomized, crossover design.

Interventions

DIETARY_SUPPLEMENTCrystalline glucosamine sulfate

A maximum single dose of 1500mg of glucosamine sulfate in a caplet.

DIETARY_SUPPLEMENTRegular glucosamine sulfate

A maximum single dose of 1500mg of glucosamine sulfate in hard gel capsules.

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

21 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Male or female aged 21- 65 years * Healthy, good physical condition * Voluntary, written, informed consent to participate in the study.

Exclusion criteria

* Serious acute or chronic diseases e.g. liver, kidney, or gastrointestinal diseases * Use of medications affecting glucosamine metabolism * Known allergies to shellfish or glucosamine * Pregnancy or breastfeeding * Participation in another investigational study

Design outcomes

Primary

Measure	Time frame	Description
AUC: the area under the concentration-time curve	0 (baseline; pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24 hours (post-dose)	To determine the gastrointestinal absorption of orally ingested glucosamine sulfate in healthy adult volunteers and compare the Area under the plasma concentration versus time curve (AUC) with that of other capsules containing glucosamine sulfate.
Cmax: maximum plasma concentration	0 (baseline; pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24 hours (post-dose)	To determine the gastrointestinal absorption of orally ingested glucosamine sulfate in healthy adult volunteers and compare the peak plasma concentration (Cmax) with that of other capsules containing glucosamine sulfate.
Tmax: the time point of maximum plasma concentration	0 (baseline; pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24 hours (post-dose)	To determine the gastrointestinal absorption of orally ingested glucosamine sulfate in healthy adult volunteers and compare the time point of maximum plasma concentration (Tmax) with that of other capsules containing glucosamine sulfate.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026